caa a22 4500 475818776 CHVBK 20180406123816.0 cr unu---uuuuu 170329e20001101xx s 000 0 eng 10.1007/s002280000179 doi (NATIONALLICENCE)springer-10.1007/s002280000179 Use of saliva and capillary blood samples as substitutes for venous blood sampling in pharmacokinetic investigations of artemisinin [Elektronische Daten] [T. Gordi, T.N. Hai, N.M. Hoai, M. Thyberg, M. Ashton] Abstract.: Objectives: Artemisinin concentrations in venous plasma, capillary plasma and saliva were compared. Methods: Eighteen Vietnamese adults with uncomplicated falciparum malaria were treated with artemisinin. Saliva, capillary and venous plasma were sampled and analysed for artemisinin using high-performance liquid chromatography with an ultraviolet detector (HPLC-UV). Results: Artemisinin capillary plasma concentrations were highly correlated to its venous plasma levels (correlation coefficient r=0.92). Capillary/venous concentration ratios were significantly higher than unity at 30min and 60min after drug intake, indicating an arterial-venous concentration difference. Artemisinin unbound fraction in plasma averaged 0.14 (SD=0.03) and was independent of drug concentration (114-1001ng/ml). Artemisinin concentrations in saliva were comparable to its unbound levels in plasma. Saliva levels were more highly correlated to unbound capillary plasma (r=0.85) than to unbound venous plasma concentrations (r=0.77). No statistically significant differences were found between the saliva, unbound venous and unbound capillary area under the curve (AUC) values. Conclusions: Capillary plasma or saliva may replace venous plasma in pharmacokinetic investigations of artemisinin. Due to the ease of collection and handling, saliva sampling can be a simple approach in field studies of artemisinin, although the lower saliva concentrations require more sensitive analytical methods. Springer-Verlag, 2000 Malaria Artemisinin Saliva nationallicence Gordi T. Division of Biopharmaceutics and Pharmacokinetics, Uppsala University, Box 580, S-75123, Uppsala, Sweden aut Hai T.N. Institute of Malariology, Parasitology and Entomology, Hanoi, Vietnam aut Hoai N.M. Phu-rieng Hospital, Binh Phuoc Province, Vietnam aut Thyberg M. Division of Biopharmaceutics and Pharmacokinetics, Uppsala University, Box 580, S-75123, Uppsala, Sweden aut Ashton M. Division of Biopharmaceutics and Pharmacokinetics, Uppsala University, Box 580, S-75123, Uppsala, Sweden aut European Journal of Clinical Pharmacology Springer-Verlag 56/8(2000-11-01), 561-566 0031-6970 56:8<561 2000 56 228 https://doi.org/10.1007/s002280000179 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280000179 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Gordi T. Division of Biopharmaceutics and Pharmacokinetics, Uppsala University, Box 580, S-75123, Uppsala, Sweden aut NATIONALLICENCE 700 1- Hai T.N. Institute of Malariology, Parasitology and Entomology, Hanoi, Vietnam aut NATIONALLICENCE 700 1- Hoai N.M. Phu-rieng Hospital, Binh Phuoc Province, Vietnam aut NATIONALLICENCE 700 1- Thyberg M. Division of Biopharmaceutics and Pharmacokinetics, Uppsala University, Box 580, S-75123, Uppsala, Sweden aut NATIONALLICENCE 700 1- Ashton M. Division of Biopharmaceutics and Pharmacokinetics, Uppsala University, Box 580, S-75123, Uppsala, Sweden aut NATIONALLICENCE 773 0- European Journal of Clinical Pharmacology Springer-Verlag 56/8(2000-11-01), 561-566 0031-6970 56:8<561 2000 56 228 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer